Sentynl gets UK MHRA’s approval for Nulibry to treat MoCD Type A
The approval was based on findings from three clinical studies that demonstrated Nulibry's safety and effectiveness in MoCD…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Apr 24
The approval was based on findings from three clinical studies that demonstrated Nulibry's safety and effectiveness in MoCD…
17 Apr 24
According to the results, Imfinzi along with chemotherapy decreased the mortality risk by 26% versus chemotherapy alone at…
17 Apr 24
Vaccine candidate provides broad coverage against the five most common groups of bacteria causing invasive meningococcal disease and…
17 Apr 24
CSafe, an active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, proudly announces the launch of…
17 Apr 24
The 89th edition of the China International Medical Equipment Fair (CMEF) witnessed an impressive turnout of over 200,000 attendees from more…
17 Apr 24
Insightec reaffirms its position at the forefront of the medical technology industry with improved functionality, safety features, and…
16 Apr 24
The multicentre, randomised, placebo-controlled APPLAUSE-IgAN trial recruited 518 adult patients with primary IgAN, who were given twice-daily doses…
12 Apr 24
Greenspace's measurement-based care platform will integrate with Welligent's cloud-based EHR software for behavioural health.
04 Apr 24
The approval for Zevtera was based on the clinical efficacy and safety data from the Phase 3 ERADICATE…
03 Apr 24
Under the deal, Genmab will gain global rights to ProfoundBio’s portfolio of next-generation ADCs which consists of three…